Roche's new breast cancer treatment Kadcyla has been rejected by NICE in draft guidance, with the cost effectiveness watchdog criticising the high price set by the company. NICE says Kadcyla costs ...

NICE has rejected Roche's breast cancer treatment Kadcyla for a second time, saying its benefits do not justify its price, even after a discount from the manufacturer. The decision has been called ...

In addition, with the launch of Perjeta in 2012, Kadcyla in 2013, and Phesgo (a subcutaneous coformulation of Herceptin and Perjeta) in 2020, Roche has somewhat refreshed its breast cancer franchise.

The cost of the drugs over a nine-month period hovers around Rs 12 lakh for Kadcyla and Rs 30 lakh for Perjeta. In India, Roche collaborated with Pune-based Emcure Pharmaceuticals to sell ...